Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

Executive Summary

There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.

Advertisement

Related Content

Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?
A Tale Of Two Committees: Which Probed EpiPen Better?
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel